Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - SARS-CoV-2 and cancer 1

LBA69 - Impact of the COVID-19 pandemic on management of medical cancer treatments and psychological consequence for the patients


19 Sep 2020


Proffered Paper - SARS-CoV-2 and cancer 1


COVID-19 and Cancer

Tumour Site


Florence Joly


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


F. Joly1, A. Leconte2, J. Grellard2, J. Lequesne2, G. Binarelli2, M. Lange2, L. Tron3, F. Gernier2, C. Rieux2, M. Fernette2, E. Bastien1, A. Morel4, B. Legrand2, D. Richard5, A. Faveyrial6, R. Travers7, L. Pépin8, O. Rigal9, F. Jardin10, B. Clarisse2

Author affiliations

  • 1 Medical Oncology Department, Centre François Baclesse, 14000 - Caen/FR
  • 2 Clinical Research, Centre Francois Baclesse, 14076 - Caen/FR
  • 3 Anticipe, Inserm U1086 Anticipe, Caen/FR
  • 4 Outpatient Department, Centre François Baclesse, 14000 - Caen/FR
  • 5 Clinical Research, Centre Henri Becquerel, Rouen/FR
  • 6 Medical Oncology, Centre François Baclesse, 14000 - Caen/FR
  • 7 Data Management Centre From Canceropole North-west, Centre Francois Baclesse, 14000 - Caen/FR
  • 8 Clinical Research, Cancer Centre Henri Becquerel, 76038 - Rouen/FR
  • 9 Medical Oncology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 10 Hematology, Centre Henri Becquerel, 76000 - Rouen/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract LBA69


Treated cancer patients (pts) are at high risk to develop severe COVID-19 evolution and guidelines proposed some preventive medical oncologic treatments (tt) adjustments. Pts had to face with this unprecedented situation, as caregivers forced to suddenly adjust their practices. We assessed the pandemic-induced therapeutic modifications of pts cancer tt and the psychological impact on pts and caregivers.


This prospective French study was initiated among pts with solid/hematologic malignancy receiving a medical tt during the lockdown in outpatient departments of 2 cancer centers. Tt modifications were collected from medical records. Perceived and post-traumatic stress (PSS, IES-R), sleep (ISI), quality of life QoL (Fact-G) and cognitive complaint (Fact-Cog) were reported at baseline (during the lockdown) and will be collected at 3 and 6 months. PSS and professional burnout/self-efficacy (MBI, GSES) were also reported by caregivers.


Baseline clinical data are available for 621 pts and questionnaires for 575 pts (93%) and 73 caregivers. Pts and caregivers median ages were 64 [24-89] and 40 [22-63], 69% and 81% women. Caregivers were mainly nurses (48%) and oncologists (30%). 98% of pts had solid tumors, 59% with metastatic disease and 47% de novo treated. Main tts included chemotherapy (72%), immunotherapy (31%) and targeted therapy (13%), 37% starting during the lockdown. 27% of pts had tt modifications including 30% adapted monitoring (mainly phone-consultation), 15% tt interruptions, 32% postponed tt, 19% administration rhythm modifications, more frequently among lung cancer, tt initiated before lockdown, immunotherapy and targeted therapy. Severe perceived stress, post-traumatic stress and insomnia were observed in 6%, 21% and 24% of pts. More pts with tt modifications presented severe post-traumatic stress (27% vs 19%, p=0.05). Tt modifications did not impact on QoL/cognition. Perceived stress score was higher among caregivers than pts (p=0.035) but 2/3 reported professional accomplishment and self efficacy.


Lockdown due to COVID-19 induced tt modification in 1/4 of pts with a majored post-traumatic stress. Despite a high level of stress, caregivers coped with the situation.

Clinical trial identification

NCT04366154, registered on 2020, April, 16th.

Editorial acknowledgement

Legal entity responsible for the study

Comprehensive Cancer Centre François Baclesse, Caen France.


French Fondation ARC (Cancer Research Association).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.